Management of Multiple Myeloma

Area of Science:

• Hematology
• Oncology
• Clinical Guidelines

Background:

• The National Comprehensive Cancer Network (NCCN) provides evidence-based guidelines for cancer treatment.
• Multiple myeloma treatment has evolved with new therapeutic agents and strategies.
• Autologous stem cell transplant (ASCT) remains a cornerstone for eligible multiple myeloma patients.

Purpose of the Study:

• To summarize the latest NCCN Guidelines for multiple myeloma treatment.
• To outline preferred and alternative therapeutic regimens.
• To highlight the role of ASCT and maintenance therapy.

Main Methods:

• Review of the most recent NCCN Guidelines for Multiple Myeloma.
• Categorization of treatment options into preferred, other, and useful in certain circumstances.
• Analysis of treatment strategies for transplant-eligible and relapsed disease settings.

Main Results:

• Bortezomib/lenalidomide/dexamethasone (category 1) and bortezomib/cyclophosphamide/dexamethasone are preferred upfront regimens for ASCT-eligible patients.
• Upfront ASCT is a preferred strategy, with tandem ASCT potentially benefiting high-risk patients.
• Lenalidomide maintenance is standard post-ASCT, improving progression-free and overall survival.
• New agents combined with bortezomib or lenalidomide improve outcomes in relapsed multiple myeloma.

Conclusions:

• The NCCN Guidelines emphasize ASCT as a preferred strategy for transplant-eligible multiple myeloma patients.
• Lenalidomide maintenance therapy is crucial for improving long-term outcomes after ASCT.
• Treatment selection for relapsed disease requires careful consideration of prior therapies and patient tolerance.